Remote results of treatment of patients with advanced ovarian cancer after interval and delayed cytoreductive surgery: a retrospective single-center study
https://doi.org/10.17650/1994-4098-2025-21-1-68-74
Abstract
Background. Neoadjuvant chemotherapy is an option for the treatment of advanced ovarian cancer. The data about optimal chemotherapy cycles before surgery is contradictory. We conducted a retrospective study to evaluate long-term outcomes following interval and delayed cytoreductive surgeries.
Aim. To compare long-term outcomes following interval and delayed cytoreductive surgeries.
Materials and methods. The study included 115 patients who suffered from advanced ovarian cancer (IIIC–IVB stages) and were operated in Moscow City Oncology Hospital No. 62 after 3–4 (interval cytoreductive surgery; n = 58) or 5–6 cycles (delayed cytoreductive surgery; n = 57) of neoadjuvant chemotherapy between January 2018 and December 2021. The primary endpoint is overall survival; secondary endpoint is disease-free survival.
Results. Median disease-free survival was 18 months in the interval cytoreductive surgery group and 16 months in the delayed cytoreductive surgery group (p >0.05). Median overall survival was 47 months in both groups (p >0.05).
Conclusion. The number of cycles of neoadjuvant chemotherapy did not affect overall and disease-free survival in patients with advanced ovarian cancer.
Supporting agencies: The authors express their gratitude to Vadim Gushchin, surgical oncologist and Director of the Cytoreductive Center at Mercy Clinic (Baltimore, USA) for critical analysis of the article and advice on its design.
About the Authors
P. I. Sorokin
Moscow City Oncology Hospital No. 62, Moscow City Healthcare Department
Russian Federation
Competing Interests:
Russian Federation
Pavel Igorevich Sorokin
27 Istra Settlement, Moscow Region 143515
Competing Interests:
The authors declare no conflict of interest
D. O. Utkin
Moscow City Oncology Hospital No. 62, Moscow City Healthcare Department
Russian Federation
Competing Interests:
Russian Federation
27 Istra Settlement, Moscow Region 143515
Competing Interests:
The authors declare no conflict of interest
M. V. Novozhilov
Moscow City Oncology Hospital No. 62, Moscow City Healthcare Department
Russian Federation
Competing Interests:
Russian Federation
27 Istra Settlement, Moscow Region 143515
Competing Interests:
The authors declare no conflict of interest
Z. T. Abduragimova
Moscow City Oncology Hospital No. 62, Moscow City Healthcare Department
Russian Federation
Competing Interests:
Russian Federation
27 Istra Settlement, Moscow Region 143515
Competing Interests:
The authors declare no conflict of interest
S. E. Kulikova
Moscow City Oncology Hospital No. 62, Moscow City Healthcare Department
Russian Federation
Competing Interests:
Russian Federation
27 Istra Settlement, Moscow Region 143515
Competing Interests:
The authors declare no conflict of interest
References
1. Erratum: Global Cancer Statistics 2018. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2020;70(4):313. DOI: 10.3322/caac.21660
2. Leonov M.G., Tikhonova E.N., Teslenko L.G. et al. Oncoepidemiological features, analysis of diagnostics and detection of ovarian cancer in Russia. Effektivnaya farmakoterapiya = Effective Pharmacotherapy 2020;16(11):18–21. (In Russ.).
3. Tyulyandina A.S., Kolomiets L.A., Morkhov K.Yu. et al. Practical recommendations for drug treatment of ovarian cancer, primary peritoneal cancer and fallopian tube cancer. Practical recommendations of the RUSSCO 3s2, 2021. Vol. 11. P. 10. (In Russ.).
4. Querleu D., Planchamp F., Chiva L. et al. European Society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery. Int J Gynecol Cancer 2017;27(7):1534–42. DOI: 10.1097/IGC.0000000000001041
5. Vergote I., Tropé C.G., Amant F. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363(10):943–53. DOI: 10.1056/NEJMoa0908806
6. Kehoe S., Hook J., Nankivell M. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial. Lancet 2015;386(9990):249–57. DOI: 10.1016/S0140-6736(14)62223-6
7. Fagotti A., Ferrandina G., Vizzielli G. et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. Eur J Cancer 2016;59:22–33. DOI: 10.1016/j.ejca.2016.01.017
8. Onda T., Satoh T., Ogawa G. et al. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. Eur J Cancer 2020;130:114–25. DOI: 10.1016/j.ejca.2020.02.020
9. Patel A., Iyer P., Matsuzaki Sh. et al. Emerging trends in neoadjuvant chemotherapy for ovarian cancer. Cancers 2021;13(4):626. DOI: 10.3390/cancers13040626
10. Bristow R.E., Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis. Gynecol Oncol 2006;103(3):1070–6. DOI: 10.1016/j.ygyno.2006.06.025
11. Plett H., Filippova O., Garbi A. et al. Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. Gynecol Oncol 2020;159(2):434–41. DOI: 10.1016/j.ygyno.2020.08.028
12. Akladios C., Baldauf J.J., Marchal F. et al. Does the number of neoadjuvant chemotherapy cycles before interval debulking surgery influence survival in advanced ovarian cancer? Oncology 2016;91(6):331–40. DOI: 10.1159/000449203
13. Bogani G., Matteucci L., Tamberi S. et al. The impact of number of cycles of neoadjuvant chemotherapy on survival of patients undergoing interval debulking surgery for stage IIIC–IV unresectable ovarian cancer: Results from a multi-institutional study. Int J Gynecol Cancer 2017;27(9):1856–62. DOI: 10.1097/IGC.0000000000001108
14. Nasioudis D., Arevalo O., Gysler S. et al. Impact of delayed interval cytoreductive surgery on the survival of patients with advanced stage high-grade epithelial ovarian carcinoma. Int J Gynecol Cancer 2024;34(1):131–7. DOI: 10.1136/ijgc-2023-004805
Review
For citations:
Sorokin P.I., Utkin D.O., Novozhilov M.V., Abduragimova Z.T., Kulikova S.E. Remote results of treatment of patients with advanced ovarian cancer after interval and delayed cytoreductive surgery: a retrospective single-center study. Tumors of female reproductive system. 2025;21(1):68-74. (In Russ.) https://doi.org/10.17650/1994-4098-2025-21-1-68-74
Views:
179
Email this article 